Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
HUTCHMED (China) ( (HK:0013) ) just unveiled an announcement.
HUTCHMED has initiated a global Phase I clinical development program for HMPL-A251, a first-in-class Antibody-Targeted Therapy Conjugate (ATTC) designed to treat patients with HER2-expressing solid tumors. This trial, conducted in the US and China, marks the first clinical-stage candidate from HUTCHMED’s next-generation ATTC platform, aiming to improve targeted delivery and reduce systemic toxicity. The development of HMPL-A251 could potentially enhance HUTCHMED’s positioning in precision oncology by offering a novel approach to overcoming challenges associated with existing PAM-targeted therapies, thus benefiting stakeholders by expanding treatment options and improving patient outcomes.
The most recent analyst rating on (HK:0013) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on HUTCHMED (China) stock, see the HK:0013 Stock Forecast page.
More about HUTCHMED (China)
HUTCHMED (China) Limited is an innovative, commercial-stage biopharmaceutical company focused on the discovery, global development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company has successfully brought drug candidates from in-house discovery to market, with its first three medicines marketed in China and one approved globally, including in the US, Europe, and Japan.
Average Trading Volume: 5,549,319
Technical Sentiment Signal: Sell
Current Market Cap: HK$18.73B
For an in-depth examination of 0013 stock, go to TipRanks’ Overview page.